Amneal Pharmaceuticals stock analysis
Amneal Pharmaceuticals (2DT) Stock Price & Analysis
2DT Stock Chart & Stats
- Day’s Range
- EUR 19.30 - EUR 19.40
- 52-Week Range
- EUR 9.80 - EUR 19.40
- Previous Close
- EUR 18.70
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.79B
- Enterprise Value
- EUR 9.98B
- Total Cash (Recent Filing)
- EUR 157.40M
- Total Debt (Recent Filing)
- EUR 3.28B
- Price to Earnings (P/E)
- 49.1
- Beta
- 0.65
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- 0.21
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified, Integrated Pharmaceutical Model
A multi-segment portfolio gives Amneal several revenue engines across volume-driven generics, branded therapies and biosimilars. Its integrated development and manufacturing capabilities can support product control, commercialization breadth and a more durable platform for launching medicines across markets.
Improving Growth And Profitability
The recovery from losses to positive TTM earnings, alongside revenue growth and stronger gross margins, indicates meaningful operating progress. If sustained, improved profitability can strengthen internal funding capacity and provide a more resilient base for continued investment in launches and capabilities.
Biosimilar Platform And Pipeline
The Kashiv combination adds research, clinical, regulatory, manufacturing and commercialization capabilities to Amneal’s biosimilar strategy. This integrated platform, paired with multiple planned launches and broad biologic exclusivity opportunities, supports a potentially durable growth avenue through the next several years.
Bears Say
High Balance-sheet Leverage
Amneal’s debt-heavy capital structure leaves less financial flexibility if operating performance weakens or integration takes longer than expected. High leverage can also constrain investment choices and make interest, refinancing and acquisition-related obligations more important to the company’s long-term execution.
Weaker Recent Cash Conversion
The recent decline in operating and free cash flow means accounting profitability is not currently translating into cash at the same rate as in prior years. Persistently weaker conversion would reduce funds available for debt reduction, capacity expansion and other strategic investments.
Modest And Historically Volatile Earnings Quality
Although profitability has improved, the relatively modest net margin leaves limited room for product, pricing or cost pressures before earnings are affected. Historical volatility also makes it harder to establish that the latest profit recovery will persist across future product and operating cycles.
Amneal Pharmaceuticals News
2DT FAQ
What was Amneal Pharmaceuticals’s price range in the past 12 months?
What is Amneal Pharmaceuticals’s market cap?
When is Amneal Pharmaceuticals’s upcoming earnings report date?
How were Amneal Pharmaceuticals’s earnings last quarter?
Is Amneal Pharmaceuticals overvalued?
Does Amneal Pharmaceuticals pay dividends?
What is Amneal Pharmaceuticals’s EPS estimate?
How many shares outstanding does Amneal Pharmaceuticals have?
What happened to Amneal Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Amneal Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Amneal Pharmaceuticals Stock Smart Score
Company Description
Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Chirag K. Patel
- Employees
- 8,700
- Website
- www.amneal.com
- Address
- 400 Crossing Boulevard, Bridgewater, NJ, 08807, US
Amneal Pharmaceuticals (2DT) Earnings & Revenues
2DT Company Deck
2DT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by double-digit Q3 revenue, EBITDA, and EPS growth; raised 2026 guidance; continued specialty-brand momentum; the completed Kashiv transaction; expanding biosimilar, complex-generic, manufacturing, and GLP-1 platforms; and a favorable 2027-2030 growth outlook. The main negatives were the expected AvKARE revenue decline, lower operating cash flow guidance due to inventory and collection timing, and temporarily higher leverage following the acquisition.
View all DE:2DT earnings summaries2DT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 4 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 12 | 0 | 0 |











